Anti-Neuroinflammatory Cannabinoid Acids as a New Therapeutic Approach for Multiple Sclerosis

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Neuroinflammation is central to multiple sclerosis (MS) pathogenesis, involving glial cell activation and immune cell infiltration.
• Current MS treatments focus on modulating immune responses to slow disease progression.

Purpose of the Study:

• To investigate the therapeutic potential of cannabinoid acids in MS.
• To assess their effects on neuroinflammatory mediators, MS symptoms, and central nervous system immune cell activity.

Main Methods:

• Assessed effects of cannabinoid acids on glial cells (BV2 microglia) stimulated with lipopolysaccharide (LPS).
• Administered cannabinoid acids intraperitoneally to MS mouse models.
• Evaluated neurological scores, glial activation (microgliosis, astrogliosis), and CD4+ T cell infiltration in spinal cord tissues.

Main Results:

• Cannabinoid acids attenuated LPS-induced nitric oxide synthase and nitric oxide release.
• Cannabidiolic acid (CBDA) increased tumor necrosis factor alpha (TNFα) secretion in stimulated cells and splenocytes from MS mice.
• CBDA administration reduced neurological scores and attenuated microgliosis, astrogliosis, and CD4+ T cell infiltration in MS mice.

Conclusions:

• Cannabinoid acids, especially CBDA, demonstrate significant therapeutic potential for MS by reducing neuroinflammation and immune cell activity.
• These compounds effectively cross the blood-brain barrier, indicating direct central nervous system action.
• CBDA's distinct immunomodulatory role, particularly its TNFα elevation, suggests novel therapeutic strategies for MS.